GLP-1 Agonists Liraglutide and Semaglutide Show No Increased Risk of Ischemic Optic Neuropathy in Large Clinical Trials
Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.
Study Design
Population
Patients from large clinical trials evaluating GLP-1 agonists.
Intervention
Liraglutide and Semaglutide, doses and routes not specified.
Outcome
Risk of ischemic optic neuropathy.
Abstract
Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.
Authors: Vilsbøll T, Arun Kumar D, Aiello LP, Rönnbäck C, Stellfeld M, Larsen LM
Journal: The British journal…